Salarius Pharmaceuticals (SLRX)

• Market cap: $2.57M
• 1 day: -13.48%
• 5 days: -36.95%
• 1 month: -46.02%
• 3 months: -70.74%
• 6 months: -77.22%
• Year to date: -90.65%
• 1 year: -88.93%
• 5 years: -99.89%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Employees: 2